Last Updated: September 28, 2026

Mallinckrodt Ireland Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for MALLINCKRODT IRELAND

MALLINCKRODT IRELAND has three approved drugs.

There are nineteen US patents protecting MALLINCKRODT IRELAND drugs.

Summary for Mallinckrodt Ireland

US Patents:	19
Tradenames:	4
Ingredients:	3
NDAs:	3

Drugs and US Patents for Mallinckrodt Ireland

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt Ireland	ACTHAR GEL	corticotropin	INJECTABLE;INJECTION	008372-006	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes	8,293,284*PED	⤷ Start Trial			Y	⤷ Start Trial
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes	8,573,209*PED	⤷ Start Trial			Y	⤷ Start Trial
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No	8,795,741*PED	⤷ Start Trial			Y	⤷ Start Trial
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No	8,573,210*PED	⤷ Start Trial			Y	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Paragraph IV (Patent) Challenges for MALLINCKRODT IRELAND drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Inhalation	100 ppm and 800 ppm	➤ Subscribe	2014-05-20

International Patents for Mallinckrodt Ireland Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Mexico	2016010359	⤷ Start Trial
Japan	2019199485	⤷ Start Trial
Australia	2013257484	⤷ Start Trial
Japan	6989571	⤷ Start Trial
European Patent Office	2269614	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Mallinckrodt Ireland Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0786264	SPC/GB08/019	United Kingdom	⤷ Start Trial	PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801
0560928	2002C/003	Belgium	⤷ Start Trial	PRODUCT NAME: NITRIC OXIDE; REGISTRATION NO/DATE: EU/1/01/194/001 20010801
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.